Company Filing History:
2 out of 1,746 
2 out of 90 
Years Active: 2013-2015
Title: The Innovations of Elliot A Gruskin
Introduction
Elliot A Gruskin is a notable inventor based in Malvern, PA (US). He has made significant contributions to the field of medical science, particularly in the treatment of demyelinating diseases and central nervous system disorders. With a total of 2 patents, his work has the potential to impact the lives of many individuals suffering from these conditions.
Latest Patents
Gruskin's latest patents focus on compositions and methods that include a recombinant human monoclonal antibody (MAB) that promotes central nervous system (CNS) remyelination. These antibodies demonstrate activity in treating demyelinating diseases and other CNS disorders of viral, bacterial, or idiopathic origin. His inventions also encompass neuromodulatory agents that include antibodies capable of binding to structures or cells in the CNS, peptide analogs, haptens, and their active fragments. The methods described in his patents aim to treat demyelinating diseases in both humans and domestic animals using various human monoclonal antibodies and polyclonal IgM antibodies. The inventions extend to the use of human antibodies, fragments, and peptide derivatives in therapeutic applications, as well as pharmaceutical compositions that can be administered in low doses to promote remyelination.
Career Highlights
Throughout his career, Elliot A Gruskin has worked with esteemed organizations such as the Mayo Foundation for Medical Education and Research and Acorda Therapeutics, Inc. His experience in these institutions has contributed to his expertise in the field of medical research and innovation.
Collaborations
Gruskin has collaborated with notable colleagues, including Eric Chojnicki and Arthur E Warrington. These partnerships have likely enhanced his research and development efforts in the medical field.
Conclusion
Elliot A Gruskin's contributions to medical science through his patents and collaborations highlight his commitment to advancing treatments for demyelinating diseases and CNS disorders. His work continues to pave the way for innovative solutions in healthcare.